{"denoms":[{"counts":[{"groupId":"BG000","value":"22"}],"units":"Participants"}],"groups":[{"description":"Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month for up to 24 total cycles.\n\nDaratumumab: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression, inability to tolerate, or 24 cycles completed.","id":"BG000","title":"Daratumumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"42","upperLimit":"83","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}]}],"title":"White Non-Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"8","upperLimit":"184","value":"48"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time since initial diagnosis","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"7","value":"2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Prior therapies","unitOfMeasure":"lines of treatment"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"180","value":"9"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Time since last plasma cell-directed treatment","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2.9","upperLimit":"854","value":"80.7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"dFLC","unitOfMeasure":"mg/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"5","value":"2"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Number of organ systems involved","unitOfMeasure":"organ systems"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}]}]}],"description":"The NYHA \\[New York Heart Association} classification of heart failure uses categories I, II, III, and IV for patients' symptoms. The higher the Class, the more symptoms of heart failure that the patient has. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest.","paramType":"COUNT_OF_PARTICIPANTS","title":"NYHA Class II or III","unitOfMeasure":"Participants"}]}